Additional Phase 2 Data Supports Further Development of Tanox's Novel HIV Therapy
December 17 2005 - 9:30AM
PR Newswire (US)
Company Presents In-Depth Analysis of TNX-355 Phase 2 Results at
45th ICAAC Meeting WASHINGTON, Dec. 17 /PRNewswire-FirstCall/ --
Tanox, Inc. (NASDAQ:TNOX) today presented further analysis of a
Phase 2 study of its novel HIV antibody, TNX-355, in a
late-breaking submission at the American Society for Microbiology's
Interscience Conference on Antimicrobial Agents and Chemotherapy
(ICAAC). The company, which recently released favorable Week 24
viral-reduction results for the drug candidate, had an abstract at
the meeting. The presentation provided details on several endpoints
of the study. In addition to meeting the primary endpoint of mean
change in viral load from baseline with statistical significance,
TNX-355, combined with an optimized background regimen (OBR),
demonstrated considerable virologic benefit compared to OBR alone
as measured by average area under the curve minus baseline
(AAUCMB). The AAUCMB for the 15 milligram-per-kilogram (mg/kg) dose
arm was a 0.97 log(10) reduction (p=0.001) in viral load by Week
24, while the AAUCMB for the 10 mg/kg dose arm was a 1.20 log(10)
reduction (p
Tanox (NASDAQ:TNOX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tanox (NASDAQ:TNOX)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about Tanox (MM) (NASDAQ): 0 recent articles
More Tanox (MM) News Articles